Get the Stockscreener App
2.91
6.68%
0.14
Equillium Inc stock is traded at $2.91, with a volume of 178.67K.
It is up +6.68% in the last 24 hours and up +0.51% over the past month.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
See More
Previous Close:
$2.77
Open:
$2.79
24h Volume:
178.67K
Relative Volume:
0.26
Market Cap:
$183.36M
Revenue:
$4.39M
Net Income/Loss:
$-22.40M
P/E Ratio:
-5.7081
EPS:
-0.5098
Net Cash Flow:
$-22.79M
1W Performance:
-7.66%
1M Performance:
+0.51%
6M Performance:
+125.57%
1Y Performance:
+826.33%
1-Day Range:
$2.68
$2.98
1-Week Range:
$2.68
$3.29
52-Week Range:
$0.2924
$3.54
Equillium Inc Stock (EQ) Company Profile
Name
Equillium Inc
Sector
Industry
Phone
(858) 412-5302
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Compare EQ vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
2.90 | 175.14M | 4.39M | -22.40M | -22.79M | -0.5098 |
VRTX
Vertex Pharmaceuticals Inc
|
524.31 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.45 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.42 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.25 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.81 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-26 | Initiated | Oppenheimer | Outperform |
| Apr-16-26 | Initiated | B. Riley Securities | Buy |
| Apr-14-26 | Initiated | Raymond James | Strong Buy |
| Apr-07-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-26 | Initiated | Roth Capital | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Mar-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-29-21 | Resumed | Stifel | Buy |
| Sep-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-14-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-10-20 | Resumed | Stifel | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
View All
Equillium Inc Stock (EQ) Latest News
Equillium(EQ) Stock Options Chain | Quotes & News - Moomoo
EQ News | EQUILLIUM INC (NASDAQ:EQ) - ChartMill
Equillium (EQ) Gets a Buy from Oppenheimer - The Globe and Mail
Roth MKM Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Equillium stock rating reaffirmed by Oppenheimer on rival drug data - Investing.com Canada
Equillium, Inc.(NasdaqCM: EQ) added to Russell 3000E Growth Benchmark - marketscreener.com
Equillium, Inc.(NasdaqCM: EQ) added to Russell 3000E Index - marketscreener.com
Equillium, Inc.(NasdaqCM: EQ) added to Russell Microcap Index - marketscreener.com
Equillium, Inc.(NasdaqCM: EQ) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Equillium Inc. (EQ) Q1 2026 Earnings: EPS Misses Estimates, Stock Gains 3.39% Amid Strategic Progress - dars.gov.et
Price to book forward of Equillium, Inc. – NASDAQ:EQ - TradingView
Price to sales forward of Equillium, Inc. – NASDAQ:EQ - TradingView
Equillium, Inc. Actuals & Estimates (NASDAQ:EQ) - TradingView
EQ Forecast — Price Target — Prediction for 2027 - TradingView
EQ Q1 2026 Earnings: EPS Miss Amid Pipeline Progress; Stock Rises 3%Special Dividend Alert - dars.gov.et
ETFs Investing in Equillium, Inc. Stocks - TradingView
Equillium Inc (EQ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
EQUILLIUM INC (EQ) Stock Chart - ChartMill
23% Of This Equillium Insider's Holdings Were Sold - simplywall.st
Equillium Inc (EQ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Equillium Inc (EQ) Institutional Confidence - TradingKey
Equillium Inc (EQ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Equillium Inc (EQ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Equillium Inc (EQ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Equillium Inc (EQ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Equillium Inc (EQ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Equillium Inc (EQ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Equillium Inc. (EQ) Jumps 8.7%: Volume Surge and Key Resistance AheadNarrow Range Breakout - dars.gov.et
Equillium Inc. (EQ) Holds Steady at $2.81 – Key Support and Resistance Levels in FocusSystematic Flow - newsline.com
Equillium’s Lead Asset EQ504 Sees Growing Analyst Confidence Amid Pipeline ProgressDividend Cut Risk - newsline.com
Analysts Grow More Confident In Equillium’s (EQ) Lead Asset EQ504 - Insider Monkey
EQ Q1 2026 Earnings: Wider-than-Expected Loss Weighs on SharesRevenue Miss Report - newsline.com
Equillium COO Christine Zedelmayer sells $42,736 in stock - Investing.com UK
Insider Sell: Stephen Connelly Sells 230,975 Shares of Equillium Inc (EQ) - GuruFocus
Equillium COO Christine Zedelmayer sells $42,736 in stock By Investing.com - Investing.com Nigeria
Equillium (NASDAQ: EQ) Form 144: insider resale activity, 200,000-share sale noted - Stock Titan
Equillium Insider Sold Shares Worth $723,830, According to a Recent SEC Filing - marketscreener.com
Equillium (EQ) COO sells 14,584 shares after exercising stock options - Stock Titan
Equillium (NASDAQ: EQ) CSO Stephen Connelly sells 230,975 shares in open market - Stock Titan
[144] Equillium, Inc. SEC Filing - Stock Titan
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory DiseaseSlideshow (NASDAQ:EQ) 2026-06-03 - Seeking Alpha
Equillium Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com
EQ Reiterated by Roth Capital -- Price Target Maintained at $12 - GuruFocus
B. Riley Securities Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Equillium links AhR activation to miR-124 as EQ504 heads toward Phase 1 - MSN
Is Equillium's AhR/miR-124 Axis the Key to Unlocking Inflammatory Disease Treatment - Kavout
Equillium Insider Sold Shares Worth $267,209, According to a Recent SEC Filing - Moomoo
Leerink Partners upgrades Equillium (EQ) - MSN
Equillium sr. vp and coo Christine Zedelmayer sells $267,209 in shares - Investing.com Australia
Equillium principal accounting officer Tom Penny sells $191,750 in stock By Investing.com - Investing.com Nigeria
Equillium Inc Stock (EQ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Equillium Inc Stock (EQ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zedelmayer Christine | Sr. Vice President and COO |
Jun 05 '26 |
Option Exercise |
0.79 |
14,584 |
11,448 |
77,170 |
| Zedelmayer Christine | Sr. Vice President and COO |
Jun 05 '26 |
Sale |
2.93 |
14,584 |
42,737 |
62,586 |
| Connelly Stephen | President and CSO |
Jun 04 '26 |
Sale |
3.16 |
200,000 |
632,760 |
793,000 |
| Connelly Stephen | President and CSO |
Jun 05 '26 |
Sale |
2.94 |
30,975 |
91,070 |
762,025 |
2.18%
2.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):